Scarica l'app Stockscreener
32.34
13.27%
3.79
Dopo l'orario di chiusura:
32.51
0.17
+0.53%
Precedente Chiudi:
$28.55
Aprire:
$29.95
Volume 24 ore:
364.86K
Relative Volume:
2.49
Capitalizzazione di mercato:
$835.68M
Reddito:
-
Utile/perdita netta:
$-184.46M
Rapporto P/E:
-0.2266
EPS:
-142.7277
Flusso di cassa netto:
$-24.11M
1 W Prestazione:
+32.60%
1M Prestazione:
-2.36%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$28.73
$33.20
Intervallo di 1 settimana:
$24.20
$33.20
Portata 52W:
$17.50
$37.90
Faeth Therapeutics Inc Stock (FTH) Company Profile
Nome
Faeth Therapeutics Inc
Settore
Industria
Telefono
(240) 243-8000
Indirizzo
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare FTH vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FTH
Faeth Therapeutics Inc
|
32.34 | 759.19M | 0 | -184.46M | -24.11M | -142.73 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Faeth Therapeutics Inc Borsa (FTH) Ultime notizie
FTH: Faeth Therapeutics, Inc.Insider Transations - Zacks Investment Research
Faeth Therapeutics (FTH) investor Caligan reports 2.4% stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH) investor Trails Edge reports 2.0% beneficial stake in 13G/A - Stock Titan
Faeth Therapeutics (FTH): Khosla Ventures group discloses 10.2% ownership stake - Stock Titan
PR News | On the Move: Finn Names Flach PartnerFri., Aug. 14, 2026 - O'Dwyer's PR
Faeth Therapeutics (FTH) investor group reports 0% ownership in amended 13G - Stock Titan
Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments - TradingView
Faeth Therapeutics Adds Senior Leaders Ahead of PIKTOR Clinical Milestones - citybiz
Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments - BioSpace
Faeth Therapeutics names two senior vice presidents - Investing.com
Faeth Therapeutics, Inc. (NASDAQ: FTH) Share Price, FTH Stock News, FTH Share Price & Updates - Kalkine
SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits
Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues (FTH) - Seeking Alpha
Faeth Therapeutics (FTH) holder files to sell 130K shares under Rule 144 - Stock Titan
Form 144 | Faeth Therapeutics(FTH.US) 10% Stockholder Proposes to Sell 3.64 Million in Common Stocks - moomoo.com
FTH Reiterated by HC Wainwright & Co. -- Price Target Maintained at $60 - GuruFocus
H.C. Wainwright Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Faeth Therapeutics Presents Pk/Pd Modeling That Informs Piktor Dose Selection in Ongoing Fth-Pik-201 Trial - marketscreener.com
Oppenheimer Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $60 - moomoo.com
Faeth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FTH Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Faeth Therapeutics (FTH) Advances Cancer Research with Merger an - GuruFocus
Faeth Therapeutics, Inc. Q2 2026: Net loss $(16.0M), EPS $(2.84) — 10-Q Summary - TradingView
Faeth Therapeutics Posts $16.0 Million Q2 Net Loss - Quiver Quantitative
Faeth Therapeutics reports $16.0M Q2 net loss, $186.4M cash and marketable securities - TradingView
FTH: Strong cash position and clinical progress with PIKTOR, topline data expected by year-end 2026 - TradingView
FTH: Net loss rose sharply to $186.2M due to acquisition costs; cash reserves stand at $186.4M - TradingView
Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates - Business Wire
FAETH THERAPEUTICS, INC : JONESTRADING INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $55 - Bitget
FTH Initiated Coverage by Raymond James -- Rating Set to Outperf - GuruFocus
Faeth Therapeutics, Inc expected to post a loss of $3.62 a shareEarnings Preview - TradingView
Raymond James Initiates Faeth Therapeutics at Outperform - marketscreener.com
Faeth Therapeutics initiated with an Outperform at Raymond James - TipRanks
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - webull.com
Faeth Therapeutics' Experimental Cancer Drug Piktor Has Upside Potential, Oppenheimer Says - marketscreener.com
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
FTH Initiates Coverage On by Oppenheimer -- Rating Set to Outper - GuruFocus
Faeth Therapeutics, Inc. (FTH) gains Khosla Ventures as reported 10% owner - Stock Titan
Faeth Therapeutics initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Faeth Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Faeth Therapeutics Ord Shs (FTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
FTH|Faeth Therapeutics Ord Shs|Price:28.290|Chg%:+0.530 - TradingKey
Faeth Therapeutics Adopts Performance-Based Stock Option Plan - TipRanks
Faeth Therapeutics grants performance options to Anand Parikh, Christopher Gerry and Josiah Craver - TradingView
Faeth Therapeutics (FTH) grants CEO 398,018 performance-based options - Stock Titan
FTH Initiated Coverage by Citizens -- Price Target Announced at $51 - GuruFocus
Faeth Therapeutics initiated with an Outperform at Citizens - TipRanks
Citizens initiates Faeth Therapeutics stock at outperform, $51 target By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Intuitive Surgical (ISRG) and Faeth Therapeutics (FTH) - The Globe and Mail
Citi Maintains Faeth Therapeutics(FTH.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Faeth Therapeutics Inc Azioni (FTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):